Accessible Search Form           Advanced Search

Gail G. Weinmann, M.D.

To arrange an interview, please contact the NHLBI Communications Office at 301-496-4236 or nhlbi_news@nhlbi.nih.gov.

Portrait of Gail Weinmann
Gail G. Weinmann, M.D.

High Res JPG file (3812 KB)

Biography

Gail G. Weinmann, M.D., is the Deputy Director of the Division of Lung Diseases (DLD) at the National Heart, Lung, and Blood Institute (NHLBI). Dr. Weinmann joined NHLBI in 1995 and has served as Deputy Director since 2008. Prior to her current appointment, Dr. Weinmann served as chief of the DLD’s Airways Biology & Disease Branch.

As Deputy Director, Dr. Weinmann oversees the direction and administration of numerous programs and initiatives that cut across the DLD’s diverse research portfolio in lung diseases. Since joining the NHLBI, Dr. Weinmann has managed a wide range of extramural lung research programs, including genetics, basic and clinical research, clinical trials, and demonstration and outreach projects.  

Dr. Weinmann received her undergraduate degree from Barnard College and her M.D. from Weil Cornell Medical School. She trained in internal medicine at Georgetown University and University of California, San Francisco and in pulmonary at Johns Hopkins.  After her pulmonary fellowship, she joined the faculty of the Johns Hopkins Bloomberg School of Public Health with a joint appointment in the School of Medicine, conducting research on the health effects of ground level ozone.


Dr. Weinmann In the News

May 18, 2014
NHLBI Media Availability: Vitamin D supplementation does not reduce asthma treatment failure in people with low Vitamin D, but some benefits suggested.
Supplementing inhaled corticosteroids (ICS) with vitamin D does not reduce the rate of treatment failure in patients with asthma and vitamin D insufficiency, finds a new NIH-funded study. The Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial randomized 408 adults with low vitamin D and mild/moderate asthma to receive the ICS ciclesonide supplemented with either high-dose vitamin D3 or placebo.

Last Updated: January 24, 2014